Lu solution is widely used in nuclear medicine, particularly in targeted radionuclide therapy. It serves as a key component in the treatment of neuroendocrine tumors and prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. The radioactive properties allow for precise delivery of radiation to cancer cells, minimizing damage to surrounding healthy tissue. Its ability to bind with specific peptides or antibodies makes it effective in both diagnostic imaging and therapeutic applications when paired with appropriate targeting molecules. Due to its favorable half-life and emission profile, it is well-suited for clinical use in outpatient settings.